Connecticut notice says Glenmark generic-drug settlement could pay eligible purchasers
A Connecticut attorney general notice says a new generic-drug antitrust settlement with Glenmark Pharmaceuticals, Inc., USA may lead to payments for eligible purchasers in participating states and territories.
A Connecticut attorney general notice dated Aug. 24 says a settlement with Glenmark Pharmaceuticals, Inc., USA may provide money to eligible purchasers of certain generic prescription drugs in participating states and territories.
The notice says the settlement is part of broader antitrust lawsuits brought by state attorneys general over allegations that several generic-drug manufacturers unlawfully agreed to fix prices. The states say the alleged conduct may have caused consumers and other purchasers to pay more than they should have for some medicines.
According to the notice, the lawsuits do not concern the safety or effectiveness of the drugs. It says Glenmark agreed to pay about $29.6 million into a settlement fund created for current and future settlements. Of that amount, $20.7 million is set aside for distribution and $8.9 million is designated for administration, litigation costs and fees if the court approves them.
The notice says no money will be distributed yet. Any payments would be made later under a plan of allocation approved by the court.
Eligibility, the notice says, is limited to people or other purchasers who bought a generic prescription drug made by a defendant and included in the litigation, with purchases made between May 1, 2009 and Dec. 31, 2019, and who live in a participating state or territory, including Washington, D.C. The notice directs readers to AGGenericDrugs.com or 1-866-290-0182 for drug listings and more detailed eligibility information.
The attorneys general say they will keep pursuing the defendants that have not settled, including Actavis, Amneal, Ascend, Aurobindo, Breckinridge, Citron, Dr. Reddy's, Emcure, Fougera, G&W, Greenstone, Lupin, Mallinckrodt, Mayne Pharma, Mylan, Par Pharmaceutical, Perrigo, Pfizer, Sandoz, Sun, Taro, Teligent, Teva, Upsher-Smith, Wockhardt and Zydus. The notice says more settlement money could be added to the fund later.
The notice also says people who do nothing will be bound by the settlement and any court decisions. Those who want to opt out must do so by Oct. 15, 2026. A court hearing to consider approval of the settlement is scheduled for Nov. 5, 2026.
People may submit objections or comments under the instructions on the settlement website, and they may appear at the hearing at their own expense, though attendance is not required. The claims process will open later, and a claim form will be posted through the website and other means.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.